The clinic surgeon as the main link in the treatment of patients with chronic ischemia of the lower extremities of atherosclerotic genesis

Introduction. An alternative way in the treatment of intermittent claudication is the use of genetic engineering technologies that lead to the stimulation of their own vasculogenesis in ischemic limbs. Treatment is carried out on an outpatient basis.Purpose: to present the results of complex conserv...

Full description

Bibliographic Details
Main Authors: Yu. V. Chervyakov, I. A. Moskovskiy
Format: Article
Language:Russian
Published: Remedium Group LTD 2022-05-01
Series:Амбулаторная хирургия
Subjects:
Online Access:https://www.a-surgeon.ru/jour/article/view/281
_version_ 1797884001182023680
author Yu. V. Chervyakov
I. A. Moskovskiy
author_facet Yu. V. Chervyakov
I. A. Moskovskiy
author_sort Yu. V. Chervyakov
collection DOAJ
description Introduction. An alternative way in the treatment of intermittent claudication is the use of genetic engineering technologies that lead to the stimulation of their own vasculogenesis in ischemic limbs. Treatment is carried out on an outpatient basis.Purpose: to present the results of complex conservative treatment using a drug based on a plasmid with the VEGF165 gene in patients with grade II CINI according to the Fontaine – A.V. Pokrovsky classification for 7 years after one course of gene therapy.Materials and methods. From 2009 to 2015, 50 patients were treated. Men – 41, women – 9. Average age 64.3 ± 10.5 years. All patients received basic therapy for atherosclerosis. In addition, a 1.2 mg gene preparation was injected twice into the muscles of the ischemic limb. The preservation of the limb, the survival rate of patients, the change in the distance of painless walking according to the treadmill test were assessed.Results and discussion. The safety of the limb after 7 years was 94%, the survival rate was 80%. Significant and moderate clinical improvement was noted in 68% of cases, satisfactory result – 6%, deterioration – 2% of patients. Only in 6% of cases there was an unfavorable outcome associated with the progression of chronic limb ischemia. All patients showed good tolerance to the drug and no side effects. Continuous conservative treatment of patients with peripheral atherosclerosis is the key factor preventing rapid progression of the disease. There is high requirement for the development of new areas of the combination treatment, which would lead to compensation of blood circulation in the extremities in peripheral atherosclerosis. The provided innovative treatment method with widespread introduction into outpatient practice will improve the quality of life of patients with intermittent claudication.Conclusions. Long-term results of treatment of patients with grade II CINI using gene therapy have been demonstrating high efficiency for 7 years. The presented innovative method of treatment, with its widespread introduction into outpatient practice, will improve the quality of life of patients with intermittent claudication by increasing the passable distance without pain in the legs, reduce the risk of ischemia progression, and minimize the burden on the healthcare system.
first_indexed 2024-04-10T03:59:37Z
format Article
id doaj.art-8c198f81592e449893f3d3668516cc7c
institution Directory Open Access Journal
issn 2712-8741
2782-2591
language Russian
last_indexed 2024-04-10T03:59:37Z
publishDate 2022-05-01
publisher Remedium Group LTD
record_format Article
series Амбулаторная хирургия
spelling doaj.art-8c198f81592e449893f3d3668516cc7c2023-03-13T07:10:19ZrusRemedium Group LTDАмбулаторная хирургия2712-87412782-25912022-05-01191515910.21518/1995-1477-2022-19-1-51-59250The clinic surgeon as the main link in the treatment of patients with chronic ischemia of the lower extremities of atherosclerotic genesisYu. V. Chervyakov0I. A. Moskovskiy1Ярославский государственный медицинский университет; Областная клиническая больницаОбластная клиническая больницаIntroduction. An alternative way in the treatment of intermittent claudication is the use of genetic engineering technologies that lead to the stimulation of their own vasculogenesis in ischemic limbs. Treatment is carried out on an outpatient basis.Purpose: to present the results of complex conservative treatment using a drug based on a plasmid with the VEGF165 gene in patients with grade II CINI according to the Fontaine – A.V. Pokrovsky classification for 7 years after one course of gene therapy.Materials and methods. From 2009 to 2015, 50 patients were treated. Men – 41, women – 9. Average age 64.3 ± 10.5 years. All patients received basic therapy for atherosclerosis. In addition, a 1.2 mg gene preparation was injected twice into the muscles of the ischemic limb. The preservation of the limb, the survival rate of patients, the change in the distance of painless walking according to the treadmill test were assessed.Results and discussion. The safety of the limb after 7 years was 94%, the survival rate was 80%. Significant and moderate clinical improvement was noted in 68% of cases, satisfactory result – 6%, deterioration – 2% of patients. Only in 6% of cases there was an unfavorable outcome associated with the progression of chronic limb ischemia. All patients showed good tolerance to the drug and no side effects. Continuous conservative treatment of patients with peripheral atherosclerosis is the key factor preventing rapid progression of the disease. There is high requirement for the development of new areas of the combination treatment, which would lead to compensation of blood circulation in the extremities in peripheral atherosclerosis. The provided innovative treatment method with widespread introduction into outpatient practice will improve the quality of life of patients with intermittent claudication.Conclusions. Long-term results of treatment of patients with grade II CINI using gene therapy have been demonstrating high efficiency for 7 years. The presented innovative method of treatment, with its widespread introduction into outpatient practice, will improve the quality of life of patients with intermittent claudication by increasing the passable distance without pain in the legs, reduce the risk of ischemia progression, and minimize the burden on the healthcare system.https://www.a-surgeon.ru/jour/article/view/281атеросклероз артерий нижних конечностейхроническая ишемияпрепарат на основе гена vegf165перемежающая хромотагенная терапия
spellingShingle Yu. V. Chervyakov
I. A. Moskovskiy
The clinic surgeon as the main link in the treatment of patients with chronic ischemia of the lower extremities of atherosclerotic genesis
Амбулаторная хирургия
атеросклероз артерий нижних конечностей
хроническая ишемия
препарат на основе гена vegf165
перемежающая хромота
генная терапия
title The clinic surgeon as the main link in the treatment of patients with chronic ischemia of the lower extremities of atherosclerotic genesis
title_full The clinic surgeon as the main link in the treatment of patients with chronic ischemia of the lower extremities of atherosclerotic genesis
title_fullStr The clinic surgeon as the main link in the treatment of patients with chronic ischemia of the lower extremities of atherosclerotic genesis
title_full_unstemmed The clinic surgeon as the main link in the treatment of patients with chronic ischemia of the lower extremities of atherosclerotic genesis
title_short The clinic surgeon as the main link in the treatment of patients with chronic ischemia of the lower extremities of atherosclerotic genesis
title_sort clinic surgeon as the main link in the treatment of patients with chronic ischemia of the lower extremities of atherosclerotic genesis
topic атеросклероз артерий нижних конечностей
хроническая ишемия
препарат на основе гена vegf165
перемежающая хромота
генная терапия
url https://www.a-surgeon.ru/jour/article/view/281
work_keys_str_mv AT yuvchervyakov theclinicsurgeonasthemainlinkinthetreatmentofpatientswithchronicischemiaofthelowerextremitiesofatheroscleroticgenesis
AT iamoskovskiy theclinicsurgeonasthemainlinkinthetreatmentofpatientswithchronicischemiaofthelowerextremitiesofatheroscleroticgenesis
AT yuvchervyakov clinicsurgeonasthemainlinkinthetreatmentofpatientswithchronicischemiaofthelowerextremitiesofatheroscleroticgenesis
AT iamoskovskiy clinicsurgeonasthemainlinkinthetreatmentofpatientswithchronicischemiaofthelowerextremitiesofatheroscleroticgenesis